Agreed, NWBO OS data was confounded DURING the trial. All patients that exhibited recurrence were given a DCVax-L dosing -- That was the confounding according to NWBO. It did not happen AFTER the trial. NWBO didn't report the PFS and naive OS until after the trial in their SEC 10K filings. It was actually happening throughout the trial. Jut read the NWBO SEC filings.
Market Data 
Markets 
AI
